E
The startup develops PEG-BHD1028, a high-affinity adiponectin receptor agonist peptide, utilizing a novel binding configuration derived from the active sequence of adiponectin receptors. This peptide aims to enhance treatment options for metabolic disorders by improving receptor activation and signaling pathways.
Anyang-si, South Korea
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops PEG-BHD1028, a high-affinity adiponectin receptor agonist peptide, utilizing a novel binding configuration derived from the active sequence of adiponectin receptors. This peptide aims to enhance treatment options for metabolic disorders by improving receptor activation and signaling pathways.